KAPA Kairos Pharma Ltd.

$KAPA extremely low float, insanely low mc, super solid data, nice big pipeline, the only downside is this is a real company , shouldnt swing. Load and hold this for massive upside. This is not a shell or dead turd. We will see if they find it.

$KAPA - perfect environment to drop POSITIVE data news. Low floaters are hot. Management should take advantage of this. 🤔

$KAPA it’s late september… behaved well post spilt tbh—trading flat w minimal bleed is a good sign. EMA gap up tap up.

$KAPA .87 to 1.25 amazing gain just in a few hours. Huge volume. Should have went so much higher. Mms wanted it walked down. Always take massive profits when i hand them to you. Im watching this closely still … its so incredibly undervalued. But when you get a free 40-50% you have to lock it in. Watching for possible reload here very closely

$KAPA banging the table on mi at .90 went to $11S called sdev yesterday after hours at 3.28 sold 5.25 this morning. KAPA next

$KAPA low floater can go like $JAGX.. KAPA has catalysts this QTR and tiny market cap. Potential market in billions.. Two catalysts ahead

$KAPA Im sorry this should be $10+ min , if you want to call me a pumper thats fine. Ive only traded biotech for 2 decades what do i know. Sometimes they get lost or mispriced, and just need the valuation corrected.

$KAPA This mornings nosedive off the high scared a lot of people away. Thats exactly what is was intended to do. Where else are you going to find a stock with very exciting phase 2 cancer data ...... with a market cap of a few million dollars. This easily has $20 pps potential.

$KAPA Phase 2 pancreatic cancer - excellent data. At 52 week low. Ridiculously low $3.8M MC. I'm back in at 1.12

$KAPA A huge that you to the noobs and weak, this is one of the best buys you can find here

$KAPA news looks good ..... 17 months vs 2 months.... just if they dropped when low floaters were hot ... oh well good luck

$KAPA Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

$KAPA I've been here for 2+ years...the recent history of this one is a spike with volume and then a drop/dump way down low....check it out on a 20/20 chart...there has always been the "possibilities" but it has been a constant dissappointment...

$KAPA Bounce off .85 inside a steep 30m downtrend needs .99 / 1.00 breakout / retest / hold to open 1.09 / 1.17 / 1.28 .90 is the first hold lose it watch .85

$KAPA OK. Done my complaining and back to the Facts: 1) Extremely good phase 2 interim PC data. 2) Other indications outside of PC. 3) Collaboration with Bayer. 4) Most importantly, a $3.1 Million market cap. I think the Quickie Mart at the end of the block has a higher market cap.

$KAPA A drop like that with that kind of volume was completely nonsensical on good news. I’m in, no brainer…

$KAPA The important addition today os the reported comparison against apalutamide alone. Not merely a higher PFS estimate. 17.7 months vs 2 months progression free survival. HUGE

$KAPA Data release soon. IMO if good it should be moon ; if not my SL is there still I may come with some profit

$KAPA “Targeting GITR for Imune Action against Tumor Progression” oral presentation tomorrow. Maybe news mañana?

$KAPA was featured in CNBC’s Microcap Minute, highlighting the Company’s approach to addressing cancer drug resistance. CEO and Chairman John Yu, M.D., discussed Kairos’ work to address treatment resistance, including its ENV-105 program targeting CD105 in prostate cancer. Watch the CNBC segment to learn more about Kairos’ approach and ongoing development programs.